Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" ...
June 11 2018 - 8:00AM
InvestorsHub NewsWire
Therapeutic Solutions International Expands Adoptive
Immunotherapy Portfolio by Incorporation of "Universal Cancer
Antigen" into StemVacs Dendritic Cell Platform
OCEANSIDE, CA
-- June
11, 2018 --
InvestorsHub NewsWire -- Therapeutics Solutions International,
Inc., (OTC
Markets:
TSOI) announced
today initiation of efforts
to combine its existing CTCFL "universal cancer
antigen", labeled
as
BRS-001, with its clinical
stage StemVacs Dendritic Cell Platform.
The Company
previously
filed a
patent on technologies covering novel means of stimulating the
immune system to kill cancer using naturally made nanoparticles
termed "exosomes"1. The patent
whose
Mexican rights are licensed
to
the Pan Am
Cancer
Treatment Centers, covers the
production and
composition of matter
of agents aimed at
immunologically
eradicating cancer
stem cells. In contrast to
previous exosome-based cancer therapeutic approaches, the
strategy disclosed in the
patent involves focusing the immune
system to attack the CTCFL
protein, which is
selectively found on cancer stem cells2.
"The
CTCFL
or
BORIS protein
represents a
unique onco-target in the fight
against cancer since
it is
only found on cancer cells and not healthy tissues.
Our
strategy possesses
the
possibility of inducing an immune response that would strike cancer
at its very
roots,
the
cancer
stem cells" said Timothy Dixon,
President and CEO of Therapeutic Solutions
International.
"The recently
approved Right to Try Law allows for accelerated clinical
development of therapeutics that possess Phase I data. We plan to
leverage this and other programs to take our scientific discoveries
from the bench to the
patient's bedside" said Dr. James
Veltmeyer, Member of the Company's Scientific Advisory
Board.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com and e-commerce at
www.youcanordernow.com.
About
Pan Am Cancer Treatment Center
Pan Am
Cancer Treatment Center contact information:
Telephone: (619)
735-9581
Diego
Rivera #2339 suite 108
Zona Rio,
Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
1 https://patents.google.com/patent/US20170143812
2 Asano et al. Oncotarget. 2016 Feb 3.
https://www.ncbi.nlm.nih.gov/pubmed/?term=26849232
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2024 to May 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From May 2023 to May 2024